| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07340827 A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG… |
Enrollment reduced: 333 -> 266 participants |
| 2026-06-12 | NCT07340827 A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG… |
date change Primary completion moved earlier: 2028-10-31 -> 2028-07-05 |
| 2026-06-12 | NCT07340827 A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG… |
date change Completion moved earlier: 2029-06-30 -> 2028-07-05 |
| 2026-06-04 | NCT06433219 Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian… |
date change Primary completion pushed: 2025-09-29 -> 2026-06-14 |
| 2026-05-29 | NCT05396833 Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune… |
date change Primary completion pushed: 2026-04-10 -> 2027-01-14 |
| 2026-05-29 | NCT05396833 Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune… |
date change Completion pushed: 2026-04-10 -> 2027-01-14 |
| 2026-05-29 | NCT06710132 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-29 | NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC… |
date change Primary completion pushed: 2026-03-30 -> 2026-09-30 |
| 2026-05-29 | NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC… |
date change Completion pushed: 2026-03-30 -> 2026-09-30 |
| 2026-05-23 | NCT06463587 Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in… |
Trial sites expanded: 133 -> 138 locations |
| 2026-05-23 | NCT06463587 Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in… |
date change Primary completion pushed: 2028-05-19 -> 2028-08-23 |
| 2026-05-23 | NCT06463587 Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in… |
date change Completion pushed: 2030-08-19 -> 2030-11-12 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07332481 | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or… | Systemic Lupus Erythematosus (SLE) | Recruiting |
| NCT07549412 | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to… | Metastatic Colorectal Cancer | Recruiting |
| NCT07355218 | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or… | Systematic Lupus Erythematosus | Recruiting |
| NCT06463587 | Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in… | Generalized Myasthenia Gravis | Recruiting |
| NCT07340827 | A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG… | Infertility | Recruiting |
| NCT03815643 | Avelumab Program Rollover Study | Solid Tumors | Active, Not Recruiting |
| Phase 2 | |||
| NCT07499362 | Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT)… | Tenosynovial Giant Cell Tumor | Recruiting |
| NCT03940703 | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC… | Non-small Cell Lung Cancer | Active, Not Recruiting |
| NCT02864992 | Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) | Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Active, Not Recruiting |
| NCT05540327 | The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) | Systemic Lupus Erythematosus | Active, Not Recruiting |
| NCT05327530 | A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in… | Locally Advanced or Metastatic Urothelial Carcinoma | Active, Not Recruiting |
| NCT06433219 | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian… | Ovarian Cancer | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05882734 | Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| NCT06710132 | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE… | Solid Tumors | Active, Not Recruiting |
| Phase 1 | |||
| NCT06577337 | Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants | Healthy | Recruiting |
| NCT06641908 | Anti-GD2 ADC M3554 in Advanced Solid Tumors | Advanced Solid Tumor | Recruiting |
| NCT07166601 | M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in… | Advanced Solid Tumor | Recruiting |
| NCT05464030 | Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | Colorectal Cancer | Recruiting |
| NCT07360314 | Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors | Advanced Solid Tumors | Recruiting |
| NCT06421935 | M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) | Advanced Solid Tumor | Active, Not Recruiting |
| NCT05081180 | Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors | Central Nervous System Tumors | Active, Not Recruiting |
| NCT04170153 | Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid… | Metastatic or Locally Advanced Unresectable Solid Tumors | Active, Not Recruiting |
| NCT06806046 | Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors | Solid Tumors | Active, Not Recruiting |
| NCT05396833 | Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune… | Metastatic or Locally Advanced Unresectable Solid Tumors | Active, Not Recruiting |
| Not specified | |||
| NCT05376891 | Met Non Small Cell Cancer Registry (MOMENT) | Cancer | Recruiting |